Pathogenesis and clinical features of psoriasis

Lancet

Volumn 370, Issue 9583, 2007, Pages 263-271

  Griffiths, Christopher EM ^a   Barker, Jonathan NWN ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; GAMMA INTERFERON; HLA ANTIGEN; HLA C ANTIGEN; HLA CW6 ANTIGEN; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

AUTOIMMUNE SKIN DISEASE; BETA HEMOLYTIC STREPTOCOCCUS; CARDIOVASCULAR DISEASE; CHROMOSOME ANALYSIS; COMORBIDITY; CYTOKINE PRODUCTION; DENDRITIC CELL; DEPRESSION; GENE LOCUS; GENETIC SUSCEPTIBILITY; HUMAN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 34447539622     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61128-3     Document Type: Review

References (91)

1. Willan R. On cutaneous diseases (1808), J Johnson, St Paul's Churchyard, London
2. Finlay A., and Coles E. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 132 (1995) 236-244
3. Griffiths C., Camp R., and Barker J. Psoriasis. In: Burns D., Breathnach S., Cox N., and Griffiths C. (Eds). Rook's textbook of dermatology. 7th edn. (2005), Blackwell, Oxford 35.1-35.69
4. Griffiths C., Christophers E., Barker J., et al. A new classification of psoriasis according to clinical phenotype. Br J Dermatol 156 (2007) 258-262
5. Martin B., Chalmers R., and Telfer N. How great is the risk of further psoriasis following a single episode of a guttate psoriasis?. Arch Dermatol 132 (1996) 717-718
6. Asumalahti K., Ameen M., Suomela S., et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 120 (2003) 627-632
7. Moll J., and Wright V. Psoriatic arthritis. Semin Arthritis Rheum 3 (1973) 55-78
8. Helliwell P., and Taylor W. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 64 (2005) ii3-ii8
9. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 4 (2003) 441-447
10. Ho P., Bruce I., Silman A., et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 52 (2005) 3596-3602
11. Pitzalis C., Cauli A., Pipitone N., et al. Cutaneous lymphocyte antigen-positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. Arthritis Rheum 39 (1996) 137-145
12. Farber E., and Nall M. The natural history of psoriasis in 5600 patients. Dermatologica 148 (1974) 1-18
13. Braathen L., Botten G., and Bjerkedak T. Prevalence of psoriasis in Norway. Acta Derm Venereol (Stockh) 142 (1989) 5-8
14. Nevitt G., and Hutchinson P. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol 135 (1996) 533-537
15. Henseler T., and Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13 (1985) 450-456
16. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
17. Neimann A., Shin D., Wang X., Margolis D., Troxel A., and Gelfand J. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 (2006) 829-835
18. Sommer D., Jenisch S., Suchan M., Christophers E., and Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298 (2006) 321-328
19. Esposito M., Saraceno R., Giunta A., Maccarone M., and Chimenti S. An Italian study on psoriasis and depression. Dermatol 212 (2006) 123-127
20. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126 (2006) 2194-2201
21. Lindelof B., Eklund G., Liden S., and Stern R. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 22 (1990) 1056-1060
22. Gelfand J., Neimann A., Shin D., Wang X., Margolis D., and Troxel A. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
23. Mallbris L., Akre O., Granath F., et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19 (2004) 225-230
24. Mrowietz U., Elder J., and Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 298 (2006) 309-318
25. Krueger J., and Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 suppl II (2005) ii30-ii36
26. Braverman I., and Yen A. Microcirculation in psoriatic skin. J Invest Dermatol 62 (1974) 493-502
27. Detmar M., Brown L., Claffey K., et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 180 (1994) 1141-1146
28. Creamer D., Allen M., Groves R., and Barker J. Circulating vascular permeability factor/vascular endothelial growth factor erythroderma. Lancet 348 (1996) 1101
29. Holash J., Maisonpierre P., Compton D., et al. Vessel cooption, regression and growth in tumors mediated by angiopoientins and VEGF. Science 284 (1999) 1994-1998
30. Kuroda K., Sapadin A., Shoji T., Fleischmajer R., and Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol 116 (2001) 713-720
31. Markham T., Mullan R., Golden-Mason L., et al. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy. J Am Acad Dermatol 54 (2006) 1003-1012
32. Bos J., de Rie M., Teunissen M., and Piskin G. Psoriasis: dysregulation of innate immunity. Br J Dermatol 152 (2005) 1098-1107
33. Valdimarsson H., Baker B., Jonsdottir I., Powles A., and Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?. Immunol Today 16 (1995) 145-149
34. Robert C., and Kupper T. Inflammatory skin diseases, T cells and immune surveillance. N Engl J Med 341 (1999) 1817-1828
35. Austin L., Ozawa M., Kikuchi T., Walters I., and Krueger J. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113 (1999) 752-759
36. Landgren E., Bråbäck L., Hedlin U., Hjern A., and Rasmussen F. Psoriasis in Swedish conscripts: time trend and association with T-helper 2-mediated disorders. Br J Dermatol 154 (2006) 332-336
37. Mueller W., and Herrmann B. Cyclosporin A for psoriasis. N Engl J Med 301 (1979) 555
38. Gottlieb S., Gilleaudeau P., Johnson R., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocytes, pathogenic basis. Nat Med 1 (1995) 442-447
39. Wahie S., Alexandruff A., Reynolds N., and Meggitt S. Psoriasis occurring after myeloablative therapy and autologous stem cell transplantation. Br J Dermatol 154 (2006) 194-195
40. Eedy D., Burrows D., Bridges J., and Jones F. Clearance of severe psoriasis after allogenic bone marrow transplantation. BMJ 300 (1990) 908
41. Vissers W., Arndtz C., Muys L., Van Erp P., de Jong E., and van de Kerkhof P. Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 150 (2004) 852-859
42. Davison S., Ballsdon A., Allen M., and Barker J. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive cells into evolving psoriatic plaques. Exp Dermatol 10 (2001) 280-285
43. Prinz J., Vollmer S., Boehncke W., Menssen A., Laisney I., and Trommler P. Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris. Eur J Immunol 29 (1999) 3360-3368
44. Gaspari A. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 54 suppl 2 (2006) S67-S80
45. Nickoloff B. Skin innate immune system in psoriasis: friend or foe?. J Clin Invest 104 (1999) 1161-1164
46. Griffiths C., Dearman R., Cumberbatch M., and Kimber I. Cytokines and Langerhans cell mobilisation in mouse and man. Cytokine 32 (2005) 67-70
47. Cumberbatch M., Singh M., Dearman R., Young H., Kimber I., and Griffiths C. Impaired Langerhans cell migration in psoriasis. J Exp Med 203 (2006) 953-960
48. Nestle F., Conrad C., Tun-Kyi A., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202 (2005) 135-143
49. Ong P., Ohtake T., Brandt C., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347 (2002) 1151-1160
50. Leonardi C., Powers J., Matheson R., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
51. Reich K., Nestle F., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
52. Farber E., Nall N., and Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 109 (1974) 207-211
53. Andressen C., and Henseler T. Inheritance of psoriasis. Analysis of 2035 family histories. Hautarzt 33 (1982) 214-217
54. Barker J. Pathophysiology of psoriasis. Lancet 338 (1991) 227-230
55. Capon F., Trembath R., and Barker J. An update on the genetics of psoriasis. Dermatol Clin 22 (2004) 339-347
56. Helms C., Cao L., Krueger J., et al. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet 35 (2003) 349-356
57. Capon F., Semprini S., Chimenti S., et al. Fine mapping of the PSORS4 psoriasis susceptibility region on chromosome 1q21. J Invest Dermatol 116 (2001) 728-730
58. Karason A., Gudjonsson J., Upmanyu R., et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 72 (2003) 125-131
59. Lee F., Bellary S., and Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 85 (1990) 962-963
60. Trembath R., Clough R., Rosbotham J., et al. Identification of a major susceptibility gene locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Human Mol Genet 6 (1997) 813-820
61. Capon F., Munro M., Trembath R., and Barker J. Searching for the MHC psoriasis susceptibility gene. J Invest Dermatol 118 (2002) 745-751
62. Suomela S., Elomaa O., Asumalahti K., et al. HCR, a candidate gene for psoriasis, is expressed differently in psoriasis and other hyperproliferative skin disorders and is downregulated by interferon-gamma in keratinocytes. J Invest Dermatol 121 (2003) 1360-1364
63. Allen M., Ishida-Yamamoto A., McGrath J., et al. Corneodesmosin expression in psoriasis vulgaris differs from normal skin and other inflammatory skin disorders. Lab Invest 81 (2001) 969-976
64. Nair R., Stuart P., Nistor I., et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78 (2006) 827-851
65. Allen M., Ameen M., Veal C., et al. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Derm 124 (2005) 103-107
66. Zenz R., Eferl R., Kenner L., et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 437 (2005) 369-375
67. Sano S., Chan K., Carbajal S., et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 11 (2005) 43-49
68. Palmer C., Irvine A., Terron-Kwiatkowski A., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38 (2006) 441-446
69. Mössner R., Kingo K., Kleensang A., et al. Association of TNF-238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Inv Dermatol 124 (2005) 282-284
70. Young H., Summers A., Bhushan M., Brenchley P., and Griffiths C. Single nucleotide polymorphisms of vascular endothelial growth factor (VEGF) in psoriasis of early onset. J Invest Dermatol 122 (2004) 209-215
71. Cargill M., Schrodi S., Chang M., et al. A large scale genetic association study confirms IL-12B and leads to IL-23R as psoriasis-risk genes. Am J Hum Genet 80 (2007) 273-290
72. Krueger G., Langley R., Leonardi C., et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 (2007) 580-592
73. Chan J., Blumenschein W., Murphy E., et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2 - dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203 (2006) 2577-2587
74. Xia Y., Li B., Hylton D., Detmar M., Yancopoulos G., and Rudge J. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102 (2003) 161-168
75. Wrone-Smith T., and Nickoloff B. Dermal injection of immunocytes induces psoriasis. J Clin Invest 98 (1996) 1878-1887
76. Nickoloff B., Bonish B., Huang B., and Porcelli S. Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 24 (2000) 212-225
77. Boyman O., Hefti H., Conrad C., Nickoloff B., Suter M., and Nestle F. Spontaneous development of psoriasis in a new models shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 199 (2004) 731-736
78. Wang H., Peters T., Kess D., et al. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116 (2006) 2105-2114
79. Stratis A., Pasparakis M., Rupec R., et al. Pathogenic role for skin macrophages in a mouse model of keratinocytes induced psoriasis-like skin inflammation. J Clin Invest 116 (2006) 2094-2104
80. Potter D. The singing detective (1986), Faber and Faber, London
81. Updike J. Self-consciousness-memoirs (1989), Deutsch, London
82. Finlay A., and Kelly S. Psoriasis-an index of disability. Clin Exp Dermatol 12 (1987) 8-11
83. Gupta M., and Gupta A. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 4 (2003) 833-842
84. Rapp S., Feldman S., Exum M., Fleischer Jr. A., and Reboussin D. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 (1999) 401-407
85. Finlay A., and Khan G. Dermatology Life Quality Index (DLQI)-a single practical measure for clinical use. Clin Exp Dermatol 19 (1994) 210-216
86. Fortune D., Richards H., Corrin A., Taylor R., Griffiths C., and Main C. Attentional bias for psoriasis-specific and psychosocial threat in patients with psoriasis. J Behav Med 26 (2003) 211-224
87. Fortune D., Richards H., Main C., and Griffiths C. Patients' strategies for coping with psoriasis. Clin Exp Dermatol 27 (2002) 177-184
88. Fortune D., Richards H., Kirby B., McElhone K., Main C., and Griffiths C. Successful treatment of psoriasis improves psoriasis-specific but not more general aspects of patients' well-being. Br J Dermatol 151 (2004) 1219-1226
89. Fortune D., Richards H., Kirby B., et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 139 (2003) 752-756
90. Richards HL, Fortune DG, Chong SL, et al. Divergent beliefs about psoriasis are associated with increased psychological distress. J Invest Dermatol 3004; 123 49-56
91. Richards H., Fortune D., Weidmann A., Sweeney S., and Griffiths C. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 151 (2004) 1227-1233